BUPROPION VS PLACEBO IN THE TREATMENT OF PATHOLOGICAL GAMBLING

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。病态赌博已成为一个主要的健康问题，特别是在赌博机会激增的情况下。尽管它很重要，但几乎没有被证明有效的治疗方案。该项目的目标是对安非他酮缓释片和安慰剂在PG治疗中进行随机、双盲比较。安非他酮将被使用，因为据报道它在治疗注意力缺陷多动障碍(ADHD)方面的疗效，以及PG和ADHD之间的临床相似之处。这项研究将是此类研究中的第一项，并有可能提供支持PG新疗法疗效的先导数据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pathological gambling (PG) has become a major health concern, particularly as gambling opportunities have proliferated. Despite its importance, there are few treatment options with proven efficacy. The goal of this project is to conduct a randomized, double-blind comparison of bupropion-SR versus placebo in the treatment of PG. Bupropion will be used because of its reported efficacy in treating attention-deficit hyperactivity disorder (ADHD), and clinical similarities between PG and ADHD. This study will be one of the first of its kind, and has the potential to provide pilot data supporting the efficacy of a novel treatment for PG.